Protocol Based-furosemide Stress Test Versus Standard Care to Evaluate Renal Recovery During Continuous Renal Replacement Therapy (PAUSE-CRRT)

C

Chiang Mai University

Status and phase

Enrolling
Phase 4

Conditions

Acute Kidney Injury

Treatments

Drug: Furosemide Injection

Study type

Interventional

Funder types

Other

Identifiers

NCT06229990
MED-2566-0034

Details and patient eligibility

About

Currently, continuous renal replacement therapy (CRRT) is the main modality for renal support in critically ill patients with hemodynamic instability. Most studies have investigated the timing of RRT initiation. However, prolonged CRRT demonstrated the association of many unexpected events, such as catheter-related complications, catheter-related blood stream infection, hypotension, hypothermia, tachycardia, and atrial fibrillation. Up to now, there is a lack of evidence regarding the timing of withholding CRRT. The furosemide stress test (FST) is a tool that is easy to use and has more availability. The investigators aimed to apply FST to evaluate renal recovery compared with standard treatment in critically ill patients undergoing CRRT.

Enrollment

40 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult 20 year of age or older
  • Acute kidney injury (AKI) stage 3 according to Kidney Disease Improving Global Outcomes (KDIGO) classification with oliguria (urine <400 ml/day)
  • Initiate CRRT in ICU (medical ICU, surgical ICU, cardiac care unit) for at least 48 hours (time for initiation and modality of CRRT can adjust by clinician)

Exclusion criteria

  • Use any inotropic drug (norepinephrine, epinephrine, dopamine, dobutamine)
  • Blood urea nitrogen (BUN) >80 mg/dL
  • Serum K <3.5 or >5 mmol/L
  • Arterial potential of Hydrogen (pH) <7.3
  • Serum bicarbonate (HCO3) <15 mmol/L
  • Urine volume <400 or >2,100 mL/day
  • Urine creatinine clearance (CrCl) at 6 hours >20 mL/min
  • Previous chronic kidney disease (CKD) stage 5 or estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2
  • Previous RRT within 14 days
  • Kidney transplantation
  • Obstructive etiology for AKI
  • Toxin/drug that necessitates RRT
  • Allergy to furosemide
  • Moribund with expected death within 24 hours
  • Pregnancy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

40 participants in 2 patient groups

Protocol based-furosemide stress test
Experimental group
Description:
Furosemide at 1.5 mg/kg intravenously
Treatment:
Drug: Furosemide Injection
Standard care
No Intervention group
Description:
Standard CRRT care without furosemide use during treatment.

Trial contacts and locations

1

Loading...

Central trial contact

Prit Kusirisin, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems